Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

290 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Pharmacology of diclofenac sodium.
Scholer DW, Ku EC, Boettcher I, Schweizer A. Scholer DW, et al. Among authors: schweizer a. Am J Med. 1986 Apr 28;80(4B):34-8. doi: 10.1016/0002-9343(86)90077-x. Am J Med. 1986. PMID: 3085490
Pharmacological properties of five diclofenac metabolites identified in human plasma.
Wiesenberg-Boettcher I, Pfeilschifter J, Schweizer A, Sallmann A, Wenk P. Wiesenberg-Boettcher I, et al. Among authors: schweizer a. Agents Actions. 1991 Sep;34(1-2):135-7. doi: 10.1007/BF01993259. Agents Actions. 1991. PMID: 1793018
A new metabolite of diclofenac sodium in human plasma.
Faigle JW, Böttcher I, Godbillon J, Kriemler HP, Schlumpf E, Schneider W, Schweizer A, Stierlin H, Winkler T. Faigle JW, et al. Among authors: schweizer a. Xenobiotica. 1988 Oct;18(10):1191-7. doi: 10.3109/00498258809042242. Xenobiotica. 1988. PMID: 3266538
Pharmacology of diclofenac sodium (Voltaren).
Scholer DW, Boettcher I, Ku EC, Schweizer A. Scholer DW, et al. Among authors: schweizer a. Semin Arthritis Rheum. 1985 Nov;15(2 Suppl 1):61-4. doi: 10.1016/s0049-0172(85)80012-3. Semin Arthritis Rheum. 1985. PMID: 3936179 No abstract available.
Combined automated writhing/motility test for testing analgesics.
Schweizer A, Brom R, Scherrer H. Schweizer A, et al. Agents Actions. 1988 Feb;23(1-2):29-31. doi: 10.1007/BF01967176. Agents Actions. 1988. PMID: 3354379 No abstract available.
Interleukin-1 enhances pain reflexes. Mediation through increased prostaglandin E2 levels.
Schweizer A, Feige U, Fontana A, Müller K, Dinarello CA. Schweizer A, et al. Agents Actions. 1988 Dec;25(3-4):246-51. doi: 10.1007/BF01965025. Agents Actions. 1988. PMID: 3265268
The pharmacological profile of CGP 28238, a novel highly potent anti-inflammatory compound.
Wiesenberg-Boettcher I, Schweizer A, Green JR, Mueller K, Maerki F, Pfeilschifter J. Wiesenberg-Boettcher I, et al. Among authors: schweizer a. Drugs Exp Clin Res. 1989;15(11-12):501-9. Drugs Exp Clin Res. 1989. PMID: 2517780
The pharmacological profile of CGP 28238, a highly potent anti-inflammatory compound.
Wiesenberg-Böttcher I, Schweizer A, Green JR, Seltenmeyer Y, Müller K. Wiesenberg-Böttcher I, et al. Among authors: schweizer a. Agents Actions. 1989 Jan;26(1-2):240-2. doi: 10.1007/BF02126625. Agents Actions. 1989. PMID: 2785341 No abstract available.
Inhibition of interleukin-1 (IL-1) enhanced pain reflexes in the rabbit by CGP 28238.
Schweizer A, Brom R, Wiesenberg-Boettcher I. Schweizer A, et al. Agents Actions. 1991 Jan;32(1-2):67-9. doi: 10.1007/BF01983314. Agents Actions. 1991. PMID: 2058476 No abstract available.
A sulphonamido-indanone derivative CGP 28237 (ZK 34228), a novel non-steroidal anti-inflammatory agent without gastro-intestinal ulcerogenicity in rats.
Böttcher I, Schweizer A, Glatt M, Werner H. Böttcher I, et al. Among authors: schweizer a. Drugs Exp Clin Res. 1987;13(5):237-45. Drugs Exp Clin Res. 1987. PMID: 3500026
290 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback